# Cold chain for cell & gene therapies Specialized courier and logistics networks that manage the temperature-controlled, chain-of-identity transport of autologous and allogeneic cell and gene therapy products between collection, manufacturing and patient-administration sites, sold by dedicated advanced-therapy-logistics providers rather than the cryogenic hardware itself. Source: https://en.bioecon.ru/technology/cold-chain-cell-gene-therapies/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: US FDA 21 CFR Part 210/211 + EU GMP Annex 1 for chain-of-identity and chain-of-custody in advanced therapy logistics | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)] Cold chain for cell and gene therapies is the logistics service layer that moves a patient's own cells (autologous) or a donor-derived product (allogeneic) between collection site, manufacturing facility and point of administration, distinct from the cryogenic tanks, freezers and shippers that provide the underlying equipment. For an autologous CAR-T therapy, the same physical unit that leaves a patient as a starting material must return to that same patient as a finished, temperature-critical product — a chain-of-identity requirement layered on top of the chain-of-custody every logistics network must maintain. A specialized courier manages the door-to-door itinerary, customs clearance for cross-border shipments, real-time temperature and location tracking, and contingency response if a flight is cancelled or a shipment is delayed, coordinating between the collection center, the manufacturing site (which may be on a different continent) and the treating hospital. This service layer sits downstream of the cryogenic hardware (EQP-066) and general biospecimen logistics (SVC-134) — it is specifically the advanced-therapy-focused courier and program-management capability, not the tanks and freezers themselves, and not general clinical-trial specimen transport. The key directions of cold chain for cell and gene therapies are: 1. **Chain-of-identity courier networks:** door-to-door logistics providers that track and preserve the one-to-one link between a patient's starting material and the finished therapy product returned to that same patient. 2. **Advanced-therapy-specific program management:** dedicated logistics coordination teams that manage the full itinerary across collection, manufacturing and administration sites, often spanning multiple countries and regulatory jurisdictions. 3. **Real-time temperature and location tracking:** connected monitoring across every leg of the shipment, with proactive alerting and contingency response for flight delays or customs holds that could jeopardize product viability. 4. **Cross-border customs and regulatory clearance:** specialized import/export handling for biological material, navigating country-specific requirements for temperature- sensitive, patient-specific therapeutic products. ### Sectoral value chain ``` [Patient/donor collection site] ──> [Chain-of-identity labeling & packaging] │ (temperature-controlled courier network) │ ▼ [Patient administration site] <─── [Customs/regulatory clearance] <─── [Manufacturing facility] ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Collection-site coordination** | The logistics provider coordinates pickup timing and initial packaging at the apheresis or biopsy collection site. | **In:** collected patient/donor material. **Out:** chain-of-identity-labeled, temperature-packaged shipment. | | **Chain-of-identity tracking** | Every shipment carries a unique identifier linking it to a specific patient, tracked end-to-end regardless of how many legs or handoffs the journey requires. | **In:** labeled shipment. **Out:** continuously tracked, identity-linked product. | | **Temperature-controlled transport** | A specialized courier network manages door-to-door transport, using cryogenic or controlled-ambient packaging matched to the product's stability profile. | **In:** identity-linked shipment. **Out:** temperature-validated product in transit. | | **Customs and regulatory clearance** | Cross-border shipments require specialized import/export handling for temperature-sensitive, patient-specific biological material. | **In:** in-transit shipment. **Out:** customs-cleared shipment, regulatory documentation. | | **Contingency management** | Real-time monitoring flags flight delays, customs holds or temperature excursions, triggering a pre-planned contingency response. | **In:** tracking data, excursion alerts. **Out:** corrective action, updated delivery plan. | | **Delivery and chain-of-custody documentation** | The product reaches the manufacturing or administration site with a complete, auditable chain-of-custody and chain-of-identity record. | **In:** delivered product. **Out:** GMP-compliant delivery and identity record. | Cross-cutting technologies of the sector: - **Chain-of-identity software platforms:** dedicated tracking systems that link each physical shipment to a specific patient record across every handoff, distinct from general shipment tracking. - **Multi-modal temperature-controlled routing:** logistics networks combine air, ground and cryogenic dry-vapor packaging to match each leg of the journey to the product's stability window. - **Proactive contingency protocols:** pre-established backup routing and courier redundancy for time- and temperature-critical shipments, reducing the risk that a single flight cancellation jeopardizes an irreplaceable patient-specific product. --- ## US The US hosts the category's leading advanced-therapy logistics providers, serving the world's largest concentration of cell and gene therapy manufacturing and clinical administration sites. ### advanced-therapy logistics network depth, chain-of-identity program management leadership - **World Courier:** positions itself specifically around chimeric antigen receptor (CAR-T) and other cell/gene therapy logistics, with dedicated program messaging around the zero-margin-for-error nature of moving these products across long distances. - **Cavalier Logistics:** provides turn-key cold chain and multi-temperature order handling for biopharma logistics, with dedicated messaging around cold-chain and pharma-logistics precision. - **Fisher Clinical Services:** manages complex sample and investigational-product logistics specifically in support of cell and gene therapy programs, including packaging, labeling and cold-chain coordination for global clinical programs. --- ## CN No China-headquartered advanced-therapy logistics provider was screened in this round; demand is driven by China's expanding cell and gene therapy clinical and commercial base, currently served largely through the same global logistics networks operating in the US and EU. ### import- and global-network-served market, domestic cell/gene therapy clinical build-out - **Global network coverage:** World Courier, Marken and other global advanced-therapy logistics providers maintain China operations serving domestic cell and gene therapy clinical trials and commercial distribution. - **Domestic cell/gene therapy build-out:** China's growing cell and gene therapy clinical and manufacturing base is the main demand driver for advanced-therapy logistics capacity, without a confirmed domestic chain-of-identity courier network identified in this screen. - **Screening note:** this screen focused on US/EU-headquartered global networks, given their established China operations; a dedicated China-originated candidate was not probed in this round. --- ## EU The United Kingdom hosts a global leader in advanced-therapy logistics specifically, with deep specialization in the cell and gene therapy chain-of-identity and program-management capability the category requires. ### advanced-therapy logistics specialization, global program-management leadership - **Marken (UK):** provides dedicated advanced-therapy logistics with published learning-center content specifically on cell and gene therapy logistics operations, positioning the company around the precision required for this therapy class rather than general pharma cold chain. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **World Courier** | 🇺🇸 USA | *CAR-T and cell/gene therapy logistics program* | Dedicated advanced-therapy courier positioning; long-distance chain-of-identity transport | Commercial | | **Marken** | 🇬🇧 UK | *Advanced therapy logistics* | Published cell/gene therapy logistics operations expertise; global network | Commercial | | **Fisher Clinical Services** | 🇺🇸 USA | *Sample and IP logistics for cell/gene therapy* | Packaging, labeling and cold-chain coordination for global clinical programs | Commercial | | **Cavalier Logistics** | 🇺🇸 USA | *Turn-key cold chain, multi-temperature order handling* | Biopharma logistics precision positioning | Commercial | --- ## Tech stack and innovations The stack layers chain-of-identity tracking, multi-modal temperature-controlled routing and cross-border regulatory clearance on a common contingency-management backbone. 1. **Chain-of-identity tracking systems:** - Dedicated software links each physical shipment to a specific patient record across every handoff, a requirement distinct from general shipment tracking because an autologous product must return to the exact same patient it originated from. - Tracking persists across collection, manufacturing and administration legs, often spanning multiple couriers, countries and regulatory jurisdictions. 2. **Multi-modal temperature-controlled routing:** - Logistics networks combine air, ground and cryogenic dry-vapor packaging to match each leg of the journey to the product's stability window, switching modes as needed to preserve product integrity. - Route planning accounts for customs-hold risk and flight-schedule reliability specifically for temperature- and time-critical patient-specific shipments. 3. **Proactive contingency protocols:** - Pre-established backup routing and courier redundancy reduce the risk that a single flight cancellation or customs delay jeopardizes an irreplaceable patient-specific product. - Real-time alerting triggers a pre-planned response the moment a temperature or schedule deviation is detected, rather than after the shipment has already been compromised. --- ## Value chains and production pipelines ### Industrial pipeline of cell/gene therapy cold-chain logistics (21 CFR Part 210/211 / EU GMP Annex 1) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Collection-site │ ───> │ 2. Chain-of-identity │ │ coordination │ │ labeling & packaging │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Customs/regulatory │ <─── │ 3. Temperature-controlled │ │ clearance │ │ transport │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Contingency management │ ───> │ 6. Delivery & documentation │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Collection-site coordination The logistics provider coordinates pickup timing and initial packaging at the apheresis or biopsy collection site, initiating the chain-of-identity record. #### Stage 2: Chain-of-identity labeling and packaging The shipment is labeled with a unique identifier linking it to a specific patient and packaged to the temperature-stability requirement of the product. #### Stage 3: Temperature-controlled transport A specialized courier network manages door-to-door transport, using cryogenic or controlled-ambient packaging matched to the product's stability profile. #### Stage 4: Customs and regulatory clearance Cross-border shipments undergo specialized import/export handling for temperature- sensitive, patient-specific biological material. #### Stage 5: Contingency management Real-time monitoring flags flight delays, customs holds or temperature excursions, triggering a pre-planned contingency response to protect product viability. #### Stage 6: Delivery and documentation The product reaches the manufacturing or administration site with a complete, auditable chain-of-custody and chain-of-identity record, meeting 21 CFR Part 210/211 and EU GMP Annex 1 documentation requirements. ---